Skip to main content
Log in

Effects of storage on the binding of carboplatin to plasma proteins

  • Short Communication
  • Carboplatin, CBDCA, Protein Binding
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Plasma ultrafiltrates are routinely used in pharmacokinetic studies of carboplatin. Experiments were performed to detect and quantitate artifactual decreases in the platinum concentration of ultrafiltrates prepared from plasma samples stored at −20°C and −70°C. Carboplatin was added to anticoagulated, whole human blood to produce a 20 μg/ml concentration. Plasma produced from the blood was stored frozen at either −20°C or −70°C. Aliquots from each storage condition were thawed and ultrafiltered once a week for up to 100 days. Platinum concentrations in ultrafiltrates and plasma were determined by flameless atomic absorption spectrometry. There was no loss of ultrafilterable platinum in plasma samples stored at −70°C, whereas there was a steady decrease in free platinum concentration in ultrafiltrates prepared from plasma samples stored at −20°C. These results imply that pharmacokinetic studies of carboplatin should use ultrafiltrates prepared immediately or that plasma for such studies should be stored at −70°C. Storage of carboplatincontaining plasma at −20°C and subsequent ultrafiltration is not acceptable, because measurement of platinum in such ultrafiltrates will be artifactually low.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bunn PA Jr, Canetta R, Ozols RF, Rozencweig M (eds) (1990) Carboplatin (JM-8). Saunders, Philadelphia

    Google Scholar 

  2. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Methods Programs Biomed 9: 115

    Google Scholar 

  3. DeConti RC, Toftness BR, Lange RC, Creasey WA (1973) Clinical and pharmacological studies withcis-diamminedichloroplatinum (II). Cancer Res 33: 3310

    Google Scholar 

  4. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A (1985) Prospective validation of pharmacologically based dosing scheme for the cisplatin analog, carboplatin. Cancer Res 45: 6502

    Google Scholar 

  5. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of carboplatin in patients with impaired renal function. Cancer Res 44: 5432

    Google Scholar 

  6. Gaver RC, George AM, Deeb G (1987) In vitro stability, plasma protein binding and blood cell partitioning of14C-carboplatin. Cancer Chemother Pharmacol 20: 271

    Google Scholar 

  7. Ghazal-Aswad S, Newell DR, Calvert AH (1991) A single sample assay for the calculation of the area under the free carboplatin plasma concentration v. time curve. Br J Cancer 63: 7

    Google Scholar 

  8. Gonias SL, Pizzo SV (1983) Complexes of serum albumin andcis-dichlorodiammineplatinum (II). J Biol Chem 258: 5764

    Google Scholar 

  9. Gormley PE, Bull JM, Leory AF, Cysyk R (1979) Kinetics ofcis-dichlorodiammineplatinum. Clin Pharmacol Ther 25: 351

    Google Scholar 

  10. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520

    Google Scholar 

  11. Laznickova A, Laznicek M, Kvetina J, Drobnik J (1986) Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats. Cancer Chemother Pharmacol 17: 133

    Google Scholar 

  12. Leroy AF, Thompson WC (1989) Binding kinetics of tetrachloro-1,2-diaminocyclohexaneplatinum (IV) (tetraplatin) andcis-diamminedichloroplatinum (II) at 37 degrees C with human plasma proteins and with bovine serum albumin. Does aquation precede protein binding? J Natl Cancer Inst 31: 427

    Google Scholar 

  13. Leroy AF, Lutz RJ, Dedrick RL, Litterst CL, Guarino AM (1979) Pharmacokinetic study ofcis-dichlorodiammineplatinum (II) (DDP) in the beagle dog: Thermodynamic and kinetic behavior of DDP in a biologic milieu. Cancer Treat Rep 63: 59

    Google Scholar 

  14. Litterst CL, Gram TE, Dedrick RL, Leroy AF, Guarino AM (1976) Distribution and disposition of platinum following intravenous administration ofcis-diamminedichloroplatinum (II). Cancer Res 36: 2340

    Google Scholar 

  15. Perera A, Jackson H, Sharma HL, McAuliffe CA, Fox BW (1992) A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro). Chem Biol Interact 35: 133

    Google Scholar 

  16. Reed E, Kohn KW (1990) Platinum analogues. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practice. Lippincott, Philadelphia, p 465

    Google Scholar 

  17. Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R (1993) Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11: 1156

    Google Scholar 

  18. Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A (1993) A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31: 324

    Google Scholar 

  19. Tosetti F, Rocco M, Fulco RA, Chiara S, Bruzzone M, Campora E, Esposito M (1988) Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin. Anticancer Res 3: 381

    Google Scholar 

  20. Vijgh WJF van der, Klein I (1986) Protein binding of five platinum compounds. Comparison of two ultrafiltration systems. Cancer Chemother Pharmacol 18: 123

    Google Scholar 

  21. Vijgh WIF van der (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21: 242

    Google Scholar 

  22. Yarbro JW, Bornstein RS, Mastrangelo MJ (eds) (1992) Carboplatin (JM-8) update: current perspectives and future directions. Semin Oncol, [Suppl 2]: 19 (1)

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erkmen, K., Egorin, M.J., Reyno, L.M. et al. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother. Pharmacol. 35, 254–256 (1995). https://doi.org/10.1007/BF00686557

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686557

Key words

Navigation